KaydedilenlerDerginizi ekleyin

Dergiler / Eurasian Journal of Medicine and Oncology / 2019 / Cilt: 3 - Sayı: 1

Eradication of Helicobacter pylori in Patients with Inflammatory Bowel Disease for Prevention of Recurrences - Impact on the Natural History of the Disease

Modesto LORENZO
Fernando AGEL
Elena MENGUAL
Sayfa
59–65
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: The eradication of H. pylori in patients with IBD may have a positive impact on the natural history of the disease, although more prospective studies are needed.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: Although, currently, it turns to speculate on infectious etiology of Crohn’s disease (CD), many studies have attributed a lower prevalence of Helicobacter pylori infection in patients with inflammatory bowel disease (IBD).
📊
Temel Bulgular & Veri:Methods: Retrospective study of 125 patients: 20 of the control group and 105 with gastrointestinal disorders.
💡
Sonuç & Katkı:Conclusion: The eradication of H. pylori in patients with IBD may have a positive impact on the natural history of the disease, although more prospective studies are needed.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objectives: Although, currently, it turns to speculate on infectious etiology of Crohn’s disease (CD), many studies have attributed a lower prevalence of Helicobacter pylori infection in patients with inflammatory bowel disease (IBD). The aim of this retrospective study was determining the benefit of detection and eradication of H. pylori in patients with IBD and its potential impact on the natural history of the disease. Methods: Retrospective study of 125 patients: 20 of the control group and 105 with gastrointestinal disorders. The 13Curea breath test was required as a routine procedure for all patients before receiving any dose of sulfasalazine. Results: Case group had an average of infection with H. pylori (42%), similar to the control group (40%). IBD showed a similar positivity to 13C-urea breath test (OR=0.99; 95% CI: 0.32–3.05). Higher incidence was found in microscopic colitis (46%) and CD (52%), than in ulcerative colitis (40%), without substantial differences. Patients treated for H. pylori, reduced the number of recurrences. Conclusion: The eradication of H. pylori in patients with IBD may have a positive impact on the natural history of the disease, although more prospective studies are needed.

🔖

Bu Makaleye Atıf Yap

LORENZO, M., AGEL, F., MENGUAL, E. (2019). Eradication of Helicobacter pylori in Patients with Inflammatory Bowel Disease for Prevention of Recurrences - Impact on the Natural History of the Disease. Eurasian Journal of Medicine and Oncology, Cilt: 3 - Sayı: 1, 59–65. https://ajindex.com/articles/126027

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Püspök A, Dejaco C, Oberhuber G, Waldhör T, Hirschl AM, Vogelsang H, et al. Influence of helicobacter pylori infection on the phenotype of Crohn’s disease-a frequent type of gastritis in patients with Crohn’s disease. Am J Gastroenterol 1999;94:3239–44
  2. Mantzaris GJ, Archavlis E, Zografos C, Zavos K, Petraki K, Triadaphyllou G. Low prevalence of Helicobacter pylori in inflammatory bowel disease: Association with sulfasalazine. Am J Gastroenterol 1995;90:1900. 3. el-Omar E, Penman I, Cruikshank G, Dover S, Banerjee S, Williams C, et al. Low prevalence of helicobacter pylori in inflammatory bowel disease: Association with sulphasalazine. Gut 1994;35:1385–8
  3. Halme L, Rautelin H, Leidenius M, Kosunen TU. Inverse correlation between helicobacter pylori infection and inflammatory bowel disease. J Clin Pathol 1996;49:65–7
  4. Wagtmans MJ, Witte AM, Taylor DR, Biemond I, Veenendaal RA, Verspaget HW, et al. Low seroprevalence of helicobacter pylori antibodies in historical sera of patients with Crohn’s disease. Scand J Gastroenterol 1997;32:712–8
  5. Väre PO, Heikius B, Silvennoinen JA, Karttunen R, Niemelä SE, Lehtola JK, et al. Seroprevalence of helicobacter pylori infection in inflammatory bowel disease: Is helicobacter pylori infection a protective factor? Scand J Gastroenterol 2001;36:1295–300
  6. Carrière J, Darfeuille-Michaud A, Nguyen HT. Infectious etiopathogenesis of Crohn’s disease. World J Gastroenterol 2014;20:12102–17
  7. Guslandi M, Fanti L, Testoni PA. Helicobacter pylori seroprevalence in Crohn’s disease: Lack of influence by pharmacological treatment. Hepatogastroenterology 2002;49:1296–7
  8. Ruuska T, Vaajalahti P, Arajärvi P, Mäki M. Prospective evaluation of upper gastrointestinal mucosal lesions in children with ulcerative colitis and Crohn’s disease. J Pediatr Gastroenterol Nutr 1994;19:181–6
  9. Oberhuber G, Hirsch M, Stolte M. High incidence of upper gastrointestinal tract involvement in Crohn’s disease. Virchows Arch 1998;432:49–52
  10. Kolho KL, Rautelin H, Lindahl H, Savilahti E. Helicobacter pylori-positive gastritis in pediatric patients with chronic inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1998;27:292–5
  11. D'Incà R, Sturniolo G, Cassaro M, di Pace C, Longo G, Callegari I, et al. Prevalence of upper gastrointestinal lesions and helicobacter pylori infection in Crohn’s disease. Dig Dis Sci 1998;43:988–92
  12. Matsumura M, Matsui T, Hatakeyama S, Matake H, Uno H, Sakurai T, et al. Prevalence of helicobacter py